BOC AND CRYOCATH LAUNCH NEW TECHNOLOGY TO FIGHT HEART DISEASE IN EUROPE

Main Menu | News By Date | News By Supplier | News By Category | About Us

BOC AND CRYOCATH LAUNCH NEW TECHNOLOGY TO FIGHT HEART DISEASE IN EUROPE
15 September 2006 - BOC Gases

A partnership between BOC and a Canadian company will see groundbreaking medical technology used to cure cardiovascular disease being made available throughout Europe.

The technology, which uses freezing temperatures to treat diseased tissue of patients with irregular heartbeats, has been developed by Montreal-based CryoCath Technologies, and has been successfully launched in North America.

CryoCath leads the world in cryotherapy products to treat cardiovascular disease. Traditionally, the use of freezing temperatures to treat diseased tissue has been limited by the inability to deliver the treatment in a minimally invasive manner. Cryocath has successfully overcome this obstacle by developing flexible, steerable, minimally invasive catheters to deliver cold therapy safely and effectively.

Having worked closely with BOC Canada, CryoCath turned to BOC Medical in the UK for help in the development of a new nitrous oxide cylinder and valve when it decided to enter the European market.

BOC designed the new cylinder and valves and collaborated with Luxfer Gas Cylinders in Nottingham and CryoCath to ensure the smooth changeover from parallel cylinder threads, as used in North America, to the EU standard of taper threads.

From its Worsley site, near Manchester, BOC now fills and ships cylinders to CryoCath's European base at Tilburg, Holland, from where they are despatched to end users across Europe.

Bill Micholuk, CryoCath Technologies materials manager, said: "Going into the European launch we at CryoCath were not familiar with the many regulatory issues concerning cylinders, valves and nitrous oxide. Had it not been for the collaboration and dedicated teamwork of BOC in managing the supply chain and guiding us through the regulatory and material requirements, nitrous oxide supply to our new customers would have been seriously impeded."

Matthew Stockwin, BOC Medical’s business development manager, said: "Thanks to the assistance of teams throughout BOC we have been able to provide CryoCath with a successful business solution. This has been a win-win for all parties, and as CryoCath business's grows across Europe, BOC is benefiting from increased orders."

BOC is the leading provider of medical gases to the UK health care industry and has been supplying the NHS for nearly 50 years. BOC Medical offers a complete line of bulk and cylinder medical gases, and gas control equipment. Medical gas mixtures include blood gas mixtures and lung diffusion mixtures. We also have anaerobic and aerobic growth mixtures as well as helium-oxygen mixtures for the treatment of breathing disorders and xenon-oxygen mixtures for CT scanning. For further details email www.bocmedical.co.uk

http://www.boc.com

About: BOC Gases
Through its PGS line of business, BOC supplies gas and related solutions to the chemicals, petroleum, glass, water services, electronic packaging, fibre optics, hydrogen energy, metals and food industries. BOC helps meet customer needs in a variety of ways, from the supply of a single gas or application through to designing, constructing and operating fully integrated gas and utilities schemes.

The BOC Group, which serves two million customers in more than 50 countries, is one of the largest and most global of the world's leading gases companies. It employs some 44,500 people worldwide and had annual sales of over £4.3 billion in 2003. Further information about The BOC Group may be obtained on the Internet at www.boc.com

The BOC Group has an international portfolio of companies grouped for management control and reporting into three lines of business: Process Gas Solutions, Industrial and Special Products, and BOC Edwards. It also has a specialist logistics business, Gist.

More News:
  • For September 2006
  • From BOC Gases
  • For Gases